Clinical efficacy of intra-cavitary infusions of autologous dendritic cell/cytokine-induced killer cell products for the treatment of refractory malignant pleural effusions and ascites.

Autologous cytokine induced killer cell immunotherapy circulating tumor DNA (ctDNA) malignant ascites malignant pleural effusion

Journal

American journal of translational research
ISSN: 1943-8141
Titre abrégé: Am J Transl Res
Pays: United States
ID NLM: 101493030

Informations de publication

Date de publication:
2020
Historique:
received: 15 03 2020
accepted: 31 05 2020
entrez: 11 8 2020
pubmed: 11 8 2020
medline: 11 8 2020
Statut: epublish

Résumé

To explore the safety and efficacy of intra-cavitary infusions of autologous mixed dendritic cell (DC)-cytokine-induced killer (CIK) cell products in advanced cancer patients with malignant pleural effusions or ascites. DC-CIKs were expanded ex vivo (mean yield of 1.36×10

Identifiants

pubmed: 32774747
pmc: PMC7407744

Types de publication

Journal Article

Langues

eng

Pagination

3940-3952

Informations de copyright

AJTR Copyright © 2020.

Déclaration de conflit d'intérêts

None.

Références

Beijing Da Xue Xue Bao Yi Xue Ban. 2008 Oct 18;40(5):486-8
pubmed: 18931710
Ann Surg Oncol. 2014 May;21(5):1474-9
pubmed: 23982251
Cancer Manag Res. 2017 Jun 23;9:229-241
pubmed: 28694705
EBioMedicine. 2019 May;43:261-269
pubmed: 31031019
Eur Respir Rev. 2016 Jun;25(140):189-98
pubmed: 27246596
Eur J Cancer. 2016 Aug;63:127-34
pubmed: 27314448
Curr Mol Med. 2009 Aug;9(6):708-24
pubmed: 19689298
J Thorac Oncol. 2016 Oct;11(10):1755-64
pubmed: 27418106
Nat Med. 2008 Sep;14(9):985-90
pubmed: 18670422
Cancer Chemother Pharmacol. 2013 Jun;71(6):1585-90
pubmed: 23589316
Oncol Lett. 2017 Sep;14(3):3379-3386
pubmed: 28927091
BMC Cancer. 2013 Jul 02;13:324
pubmed: 23816056
Clin Cancer Res. 2017 Sep 1;23(17):5066-5073
pubmed: 28611200
Cancer Immunol Immunother. 2014 Sep;63(9):939-46
pubmed: 24916038
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
JAMA. 2012 Jun 13;307(22):2383-9
pubmed: 22610520
Int J Cancer. 2017 Jun 15;140(12):2642-2647
pubmed: 28124376
Arch Gynecol Obstet. 2013 Sep;288(3):581-5
pubmed: 23644922
Ann Am Thorac Soc. 2019 Jan;16(1):59-61
pubmed: 30592448
Nat Rev Drug Discov. 2006 Mar;5(3):219-34
pubmed: 16518375
Nat Rev Drug Discov. 2020 Mar;19(3):200-218
pubmed: 31907401
Oncoimmunology. 2019 Jan 22;8(4):e1554969
pubmed: 30906651
Nat Rev Clin Oncol. 2019 Mar;16(3):151-167
pubmed: 30523282
Ann Oncol. 2012 Aug;23(8):1979-1985
pubmed: 22734013
Clin Transl Oncol. 2019 Jun;21(6):721-728
pubmed: 30374838
Nat Rev Cancer. 2013 Apr;13(4):273-82
pubmed: 23426401
Oncotarget. 2015 Dec 1;6(38):41350-9
pubmed: 26462021
JAMA. 2017 Nov 21;318(19):1903-1912
pubmed: 29164255
Lancet Oncol. 2012 Feb;13(2):154-62
pubmed: 22192729
JAMA. 2018 Apr 10;319(14):1507-1508
pubmed: 29634827
J Clin Immunol. 2007 May;27(3):317-26
pubmed: 17468835
Int J Cancer. 2020 Mar 1;146(5):1359-1368
pubmed: 31241775
Lancet Respir Med. 2020 Jun;8(6):609-618
pubmed: 31669226
Thorax. 2010 Aug;65 Suppl 2:ii32-40
pubmed: 20696691
Clin Cancer Res. 2019 Mar 1;25(5):1494-1504
pubmed: 30514775

Auteurs

Zixuan He (Z)

Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University Beijing 100038, China.

Shuo Wang (S)

Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University Beijing 100038, China.

Guoliang Qiao (G)

Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University Beijing 100038, China.

Xiaoli Wang (X)

Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University Beijing 100038, China.

Xinna Zhou (X)

Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University Beijing 100038, China.

Siyu Zhu (S)

Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University Beijing 100038, China.

Yanhua Yuan (Y)

Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University Beijing 100038, China.

Michael A Morse (MA)

Department of Medicine, Duke University Medical Center Durham, NC 27710, USA.
Department of Surgery, Duke University Medical Center Durham, NC 27710, USA.

Amy Hobeika (A)

Department of Surgery, Duke University Medical Center Durham, NC 27710, USA.

Jun Ren (J)

Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University Beijing 100038, China.
Department of Surgery, Duke University Medical Center Durham, NC 27710, USA.

Herbert Kim Lyerly (HK)

Department of Surgery, Duke University Medical Center Durham, NC 27710, USA.

Classifications MeSH